FcIgG-GE11-Melittin as a novel EGFR targeted peptibody with potent cytotoxic activity against cancer cells

References

Normanno, N. et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2–16 (2006).

Google Scholar
Wee, P. & Wang, Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 9, (2017).
Sigismund, S., Avanzato, D. & Lanzetti, L. Emerging functions of the EGFR in cancer. Mol. Oncol. 12, 3–20 (2018).

Google Scholar
Huang, C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology. Curr. Opin. Biotechnol. 20, 692–699 (2009).

Google Scholar
Rady, I., Siddiqui, I. A., Rady, M. & Mukhtar, H. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett. 402, 16–31 (2017).

Google Scholar
Raghuraman, H. & Chattopadhyay, A. Melittin: a Membrane-active peptide with diverse functions. Biosci. Rep. 27, 189–223 (2007).

Google Scholar
Guha, S. et al. Applications and evolution of melittin, the quintessential membrane active peptide. Biochem. Pharmacol. 193, 114769 (2021).

Google Scholar
Oršolić, N. Bee venom in cancer therapy. Cancer Metastasis Rev. 31, 173–194 (2012).

Google Scholar
Wehbe, R. et al. Bee venom: overview of main compounds and bioactivities for therapeutic interests. Molecules 24, (2019).
Pandey, P., Khan, F., Khan, M. A., Kumar, R. & Upadhyay, T. K. An Updated Review Summarizing the Anticancer Efficacy of Melittin from Bee Venom in Several Models of Human Cancers. Nutrients 15, (2023).
Yin, H. et al. The hybrid oncolytic peptide NTP-385 potently inhibits adherent cancer cells by targeting the nucleus. Acta Pharmacol. Sin. 44, 201–210 (2023).

Google Scholar
Yin, H. et al. Design, synthesis and anticancer evaluation of novel oncolytic peptide-chlorambucil conjugates. Bioorg. Chem. 138, 106674 (2023).

Google Scholar
Qi, Y. K., Zheng, J. S. & Liu, L. Mirror-image protein and peptide drug discovery through mirror-image phage display. Chem 10, 2390–2407 (2024).

Google Scholar
Fu, X. Y. et al. Three rounds of Stability-Guided optimization and systematical evaluation of oncolytic peptide LTX-315. J. Med. Chem. 67, 3885–3908 (2024).

Google Scholar
Gajski, G., Garaj-Vrhovac, V. & Melittin A lytic peptide with anticancer properties. Environ. Toxicol. Pharmacol. 36, 697–705 (2013).

Google Scholar
Soman, N. R. et al. Molecularly targeted nanocarriers deliver the cytolytic peptide Melittin specifically to tumor cells in mice, reducing tumor growth. J. Clin. Invest. 119, 2830–2842 (2009).

Google Scholar
Li, Z. J. et al. A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery. J. Control Release. 148, 292–302 (2010).

Google Scholar
Hallaji, M. et al. Targeted cancer treatment using a novel EGFR-specific Fc-fusion peptide based on GE11 peptide. Sci. Rep. 15, 5107 (2025).

Google Scholar
Araste, F. et al. Peptide-based targeted therapeutics: focus on cancer treatment. J. Control Release. 292, 141–162 (2018).

Google Scholar
Rizkallah, J. et al. Melittin-Based Nanoparticles for Cancer Therapy: Mechanisms, Applications, and Future Perspectives. Pharmaceutics 17, (2025).
Jadhav, V. et al. Bee venom loaded nanomaterials for cancer therapy: a novel approach. Discov Mater. 5, 92 (2025).

Google Scholar
Beck, A., Wurch, T., Bailly, C. & Corvaia, N. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10, 345–352 (2010).

Google Scholar
Nimmerjahn, F. & Ravetch, J. V. Fcγ receptors as regulators of immune responses. Nat. Rev. Immunol. 8, 34–47 (2008).

Google Scholar
Wessman, P., Strömstedt, A. A., Malmsten, M. & Edwards, K. Melittin-lipid bilayer interactions and the role of cholesterol. Biophys. J. 95, 4324–4336 (2008).

Google Scholar
Sabapathy, T., Deplazes, E. & Mancera, R. L. Revisiting the interaction of Melittin with phospholipid bilayers: the effects of concentration and ionic strength. Int. J. Mol. Sci. 21, 746–766 (2020).

Google Scholar
Park, M. H. et al. Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB. Prostate 71, 801–812 (2011).

Google Scholar
Lim, H. N., Baek, S. B. & Jung, H. J. Bee venom and its peptide component Melittin suppress growth and migration of melanoma cells via Inhibition of PI3K/AKT/mTOR and MAPK pathways. Molecules 24, 929–942 (2019).

Google Scholar
Li, X. et al. Melittin induces ferroptosis and ER stress-CHOP-mediated apoptosis in A549 cells. Free Radic Res. 56, 398–410 (2022).

Google Scholar
Nikodijević, D. et al. Impact of bee venom and Melittin on apoptosis and biotransformation in colorectal carcinoma cell lines. Toxin Rev. 40, 1–8 (2019).

Google Scholar
Askari, P., Namaei, M. H., Ghazvini, K. & Hosseini, M. In vitro and in vivo toxicity and antibacterial efficacy of Melittin against clinical extensively drug-resistant bacteria. BMC Pharmacol. Toxicol. 22, 42 (2021).

Google Scholar
Cheng, B. & Xu, P. Redox-Sensitive nanocomplex for targeted delivery of Melittin. Toxins 12, 582–595 (2020).

Google Scholar
Frese, K. K. & Tuveson, D. A. Maximizing mouse cancer models. Nat. Rev. Cancer. 7, 654–658 (2007).

Google Scholar
Kerbel, R. S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2, 134–139 (2003).

Google Scholar
Harding, F. A., Stickler, M. M., Razo, J. & DuBridge, R. B. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2, 256–265 (2010).

Google Scholar
Hallaji, M., Parhamfar, M., Raoufi, E. & Abtahi, H. Cloning and High-Level expression of the enzymatic region of phytase in E. coli. Int. J. Pept. Res. Ther. 25, 1431–1439 (2019).

Google Scholar

Download references